Development of novel diagnosis and therapeutic procedures for nasal NK/T-cell lymphoma consists of targeting EBV-associated molecules

2017 Fiscal Year Final Research Report

• Project/Area Number: 15H04986
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Otorhinolaryngology
• Research Institution: Asahikawa Medical College
• Principal Investigator: Harabuchi Yasuaki 旭川医科大学, 医学部, 教授 (80208686)
• Co-Investigator(Kenkyū-buntansha): 高原 幹 旭川医科大学, 医学部, 講師 (50322904) ; 長門 利純 旭川医科大学, 医学部, 助教 (80431419) ; 岸部 幹 旭川医科大学, 医学部, 講師 (80447101) ; 小林 博也 旭川医科大学, 医学部, 教授 (90280867) ; 上田 征吾 旭川医科大学, 医学部, 助教 (90447102) ; 駒林 優樹 旭川医科大学, 医学部, 助教 (40548864)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 頭頸部外科学

Outline of Final Research Achievements

We generated murine xenograft models inoculated with an natural killer/T-cell lymphoma cell line and revealed that sPD-L1 could be a prognostic predictor for NNKTL and open up the pos- sibility of immunotherapy of this lymphoma using PD-1/ PD-L1 axis inhibitors.
We revealed that circulating EBV‐miRNAs, particularly miR‐BART2‐5p, may serve as potential diagnostic and prognostic biomarkers in patients with nasal natural killer/T-cell lymphoma.

Free Research Field

悪性腫瘍